Biomarkers of Myocardial Cell Damage: Heart-Type Fatty Acid Binding Protein (H-FABP) for the Early Evaluation of Suspected Acute Coronary Syndrome

Willemsen, Robert; Dinant, Geert Jan; Glatz, Jan F. C.

doi:10.1007/978-94-007-7678-4_43

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to troponin, H-FABP is released in the presence of myocardial damage, such as ischemia, which is why it is considered an early indicator for ischemic heart damage. Elevated H-FABP levels at hospital admission are predictors of a lethal outcome, as well as non-fatal cardiac adverse events, even in absence of troponin elevations [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome

et al. 2021

View full text Add to dashboard Cite

Introduction Takotsubo syndrome (TTS) is clinically indistinguishable from an acute coronary syndrome (ACS). In the absence of valid markers for differential diagnosis, coronary angiography has been indispensable. Methods In our study, we evaluated the serum levels of sST-2, GDF-15, suPAR and H-FABP in 92 patients with the suspicion of TTS (51 TTS and 41 ACS patients) and 40 gender matched controls (no coronary artery disease or signs of heart failure) at baseline. Results H-FABP was significantly higher in ACS patients compared to TTS patients. Even in in propensity score matching for left ventricular ejection fraction, sex and cardiovascular risk factors, differences in the plasma levels of H-FABP in the matched cohort of TTS vs ACS remained statistically significant. Whereas, sST-2 was significantly elevated in TTS patients. H-FABP was superior for prediction of an ACS with even higher accuracy than hs troponin in differential diagnosis (AUC 0.797, p ≤ 0.0001); the optimal cut off for discrimination towards a TTS was calculated as 2.93 ng/ml (sensitivity 70.0%, specificity 82.4%, PPV 75.7%, NPV 77.4%). sST-2 seemed most appropriate for identification of a TTS (AUC 0.653, p = 0.012). The optimal cut off for differential diagnosis was 11018.06 pg/ml (sensitivity 82.0%, specificity 51.2%, PPV 69.4%, NPV 71.9 %). Conclusion H-FABP and sST-2 are the most promising markers with better accuracy than preexisting biomarkers in differential diagnosis in our study and therefore, could be crucial for the guidance of treatment in patients with high bleeding risk, advanced renal failure or multimorbidity. Graphical abstract

show abstract

Section: Introductionmentioning

confidence: 99%

The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similar to troponin, H-FABP is released in the presence of myocardial damage, such as ischemia, why it is considered as an early indicator for ischemic heart damage. Increased H-FABP levels at hospital admission are predictive for lethal outcome, as well as for non-fatal cardiac adverse events, even in absence of troponin elevations ( 30 ).…”

Section: Introductionmentioning

confidence: 99%

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies

Topf

Mirna

Bacher

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Introduction: Among the causes of de novo diagnosed cardiomyopathy, Takotsubo cardiomyopathy (TTC) plays a minor role, with an occurrence of 50,000–100,000 cases per annum in the United States. In clinical practice, a differentiation of a TTC toward an ischemic cardiomyopathy (ICMP) or a dilatative cardiomyopathy (DCMP) appears to be challenging, especially in a subacute setting or in atypical types of TTC.Methods: To investigate this issue, we analyzed serum levels of sST2, GDF-15, suPAR, HFABP, and clinical parameters including echocardiography in 51 patients with TTC, 52 patients with ischemic cardiomyopathy (ICMP) and 65 patients with dilated cardiomyopathy (DCMP).Results: sST-2 seemed to be the most promising biomarker for prediction of a TTC in differential diagnosis to an ICMP (AUC: 0.879, p = < 0.001, Cut off values: 12,140.5 pg/ml) or to a DCMP (AUC: 0.881, p = < 0.001, cut off value: 14521.9 pg/ml). GDF-15 evidenced a slightly lower AUC for prediction of a TTC in differential diagnosis to an ICMP (AUC: 0.626, p = 0.028) and to a DCMP (AUC: 0.653, p = 0.007). A differential diagnostic value was found for H-FABP in the prediction of a DCMP compared to TTC patients (AUC: 0.686, p = < 0.001). In propensity score matching for left ventricular ejection fraction, sex, and cardiovascular risk factors, differences in the plasma levels of sST2 and H-FABP in the matched cohort of TTC vs. DCMP remained statistically significant. In the matched cohort of TTC vs. ICMP, differences in sST2 also remained statistically significantConclusion: As medical therapy, long term prognosis, interval of follow-ups, rehabilitation program and recommendations differ completely between TTC and ICMP/DCMP, biomarkers for differential diagnosis, or rather for confirmation of diagnosis, are warranted in cases of cardiomyopathies with unsure origin. sST-2, GDF-15 and H-FABP might facilitate the classification.

show abstract

Data_Sheet_1.docx

View full text Add to dashboard Cite

Biomarkers of Myocardial Cell Damage: Heart-Type Fatty Acid Binding Protein (H-FABP) for the Early Evaluation of Suspected Acute Coronary Syndrome

Cited by 3 publications

References 95 publications

The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome

The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies

Data_Sheet_1.docx

Contact Info

Product

Resources

About